Abstract: The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.

Abstract: A milking device includes a vessel and cover plate. The vessel and the cover plate form a sealed volume that is internally divided into a collecting chamber, a vacuum chamber and an air intake chamber. The collecting chamber is arranged between the vacuum chamber and the air intake chamber. The vessel has a first internal wall that separates the collecting chamber from the air intake chamber, with a first passage between the collecting chamber and the air intake chamber arranged at the first internal wall. The vessel has a second internal wall that separates the collecting chamber from the vacuum chamber, with a second passage between the collecting chamber and the vacuum chamber arranged at the second internal wall.

Abstract: A milking device includes a vessel and cover plate. The vessel and the cover plate form a sealed volume that is internally divided into a collecting chamber, a vacuum chamber and an air intake chamber. The collecting chamber is arranged between the vacuum chamber and the air intake chamber. The vessel has a first internal wall that separates the collecting chamber from the air intake chamber, with a first passage between the collecting chamber and the air intake chamber arranged at the first internal wall. The vessel has a second internal wall that separates the collecting chamber from the vacuum chamber, with a second passage between the collecting chamber and the vacuum chamber arranged at the second internal wall.

Abstract: The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.

Abstract: The present invention provides a method for the part purification of fibrinogen from milk, the method comprising the transfer of protease enzyme which is present in the milk, into the whey phase with the removal or partition of fibrinogen into another phase of the milk. The present invention also provides a method for obtaining fibrinogen from a fluid, the method comprising: a) contacting the fluid with a hydrophobic interaction chromatography resin under conditions where the fibrinogen binds to the resin; and b) removing the bound protein by means of elution.

Abstract: The present invention provides a method for the part purification of fibrinogen from milk, the method comprising the transfer of protease enzyme which is present in the milk, into the whey phase with the removal or partition if fibrinogen into another phase of the milk. The present invention also provides a method for obtaining fibrinogen from a fluid, the method comprising: a) contacting the fluid with a hydrophobic interaction chromatography resin under conditions where the fibrinogen binds to the resin; and b) removing the bound protein by means of elution.

Abstract: A process for the production of a peptide is disclosed, the process comprising expressing in the milk of a transgenic, non-human, placental mammal a fusion protein which comprises the peptide to be expressed linked to a fusion partner protein which is lysozyme. The fusion protein may be separate from the milk and cleaved to yield the target peptide. A transgenic, non-human, placental mammal whose genome incorporates a DNA molecule comprising a coding sequence encoding lysozyme coupled to a peptide is also described.